Published in Eur J Pharmacol on December 04, 2007
Hyperpolarization-activated cyclic nucleotide-gated channels in olfactory sensory neurons regulate axon extension and glomerular formation. J Neurosci (2010) 0.92
High throughput screening technologies for ion channels. Acta Pharmacol Sin (2015) 0.86
Local loperamide injection reduces mechanosensitivity of rat cutaneous, nociceptive C-fibers. PLoS One (2012) 0.75
Expression and function of a CP339,818-sensitive K⁺ current in a subpopulation of putative nociceptive neurons from adult mouse trigeminal ganglia. J Neurophysiol (2015) 0.75
HCN Channels Modulators: The Need for Selectivity. Curr Top Med Chem (2016) 0.75
Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci (2010) 2.78
Screening technologies for ion channel drug discovery. Future Med Chem (2010) 1.58
Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol (2007) 1.44
A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther (2009) 1.31
Two N-terminal domains of Kv4 K(+) channels regulate binding to and modulation by KChIP1. Neuron (2004) 1.30
Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Curr Top Med Chem (2010) 1.21
Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res (2006) 1.15
Test-retest stability analysis of resting brain activity revealed by blood oxygen level-dependent functional MRI. J Magn Reson Imaging (2012) 1.09
Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide). J Pharmacol Exp Ther (2008) 1.07
Amiloride is neuroprotective in an MPTP model of Parkinson's disease. Neurobiol Dis (2008) 1.07
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci (2014) 1.06
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol (2002) 1.04
Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS One (2013) 1.03
Voltage- and Temperature-Dependent Allosteric Modulation of α7 Nicotinic Receptors by PNU120596. Front Pharmacol (2011) 1.02
hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk. Curr Drug Metab (2008) 1.02
Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol (2010) 1.02
Ligand dependency of 5-hydroxytryptamine 2C receptor internalization. J Pharmacol Exp Ther (2004) 1.00
Targeting the cholinergic system as a therapeutic strategy for the treatment of pain. Neuropharmacology (2007) 1.00
The role of calsenilin/DREAM/KChIP3 in contextual fear conditioning. Learn Mem (2009) 1.00
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem (2013) 0.99
Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther (2009) 0.99
Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med (2013) 0.98
Functional properties of alpha7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a stable recombinant CHO-K1 cell line. Assay Drug Dev Technol (2008) 0.94
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl) (2007) 0.94
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. Ann Neurol (2014) 0.92
Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological models. Psychopharmacology (Berl) (2008) 0.92
A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther (2007) 0.91
Direct inhibition of Ih by analgesic loperamide in rat DRG neurons. J Neurophysiol (2007) 0.91
The four major N- and C-terminal splice variants of the excitatory amino acid transporter GLT-1 form cell surface homomeric and heteromeric assemblies. Mol Pharmacol (2009) 0.90
Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action. Mol Pharmacol (2007) 0.90
Evaluation of FLIPR Calcium 3 Assay Kit--a new no-wash fluorescence calcium indicator reagent. J Biomol Screen (2003) 0.89
Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology (2013) 0.89
The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther (2011) 0.87
mGlu4 potentiation of K(2P)2.1 is dependant on C-terminal dephosphorylation. Mol Cell Neurosci (2007) 0.87
5-HT2C receptor agonists as an innovative approach for psychiatric disorders. Drug News Perspect (2007) 0.86
Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol (2003) 0.85
The role of transmembrane helix 5 in agonist binding to the human H3 receptor. J Pharmacol Exp Ther (2002) 0.85
Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators). Bioorg Med Chem (2007) 0.85
Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons. J Neurochem (2014) 0.84
Role of the GLT-1 subtype of glutamate transporter in glutamate homeostasis: the GLT-1-preferring inhibitor WAY-855 produces marginal neurotoxicity in the rat hippocampus. Eur J Neurosci (2005) 0.84
5-HT(2C) agonists as therapeutics for the treatment of schizophrenia. Handb Exp Pharmacol (2012) 0.84
The C-terminus of Gi family G-proteins as a determinant of 5-HT(1A) receptor coupling. Biochem Biophys Res Commun (2002) 0.83
Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol (2005) 0.82
Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg Med Chem Lett (2004) 0.81
Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors. Bioorg Med Chem Lett (2005) 0.81
Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release. Eur J Pharmacol (2010) 0.80
Pituitary adenylate cyclase-activating peptide (PACAP) induces differentiation in the neuronal F11 cell line through a PKA-dependent pathway. Brain Res (2006) 0.80
Validation of DRG-like F11 cells for evaluation of KCNQ/M-channel modulators. Assay Drug Dev Technol (2006) 0.79
Genetic and functional analysis of human P2X5 reveals a distinct pattern of exon 10 polymorphism with predominant expression of the nonfunctional receptor isoform. Mol Pharmacol (2010) 0.79
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology (Berl) (2011) 0.78
Development of an improved IP(1) assay for the characterization of 5-HT(2C) receptor ligands. Assay Drug Dev Technol (2010) 0.78
Pharmacological characterization of antiepileptic drugs and experimental analgesics on low magnesium-induced hyperexcitability in rat hippocampal slices. Brain Res (2005) 0.78
Synthesis and biological activities of aryl-ether-, biaryl-, and fluorene-aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT-2. Bioorg Med Chem Lett (2005) 0.78
Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells. J Neurosci Methods (2007) 0.78
SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorg Med Chem (2009) 0.78
Functional calcium coupling with the human metabotropic glutamate receptor subtypes 2 and 4 by stable co-expression with a calcium pathway facilitating G-protein chimera in Chinese hamster ovary cells. Biochem Pharmacol (2003) 0.78
Scintillation proximity assay in lead discovery. Expert Opin Drug Discov (2008) 0.77
Validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel enhancers using IonWorks HT. J Biomol Screen (2007) 0.77
WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system. J Neurochem (2006) 0.77
Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the ion Channel Reader 8000. Assay Drug Dev Technol (2004) 0.76
Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease. Int J Neuropsychopharmacol (2012) 0.76
Development of a novel automated ion channel recording method using "inside-out" whole-cell membranes. J Biomol Screen (2005) 0.75
A novel high-throughput screening assay for HCN channel blocker using membrane potential-sensitive dye and FLIPR. J Biomol Screen (2009) 0.75
N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate. J Med Chem (2012) 0.75
Development of a scintillation proximity assay binding method for the human 5-hydroxytryptamine 6 receptor using intact cells. Anal Biochem (2008) 0.75
Ion channel screening plates: design, construction, and maintenance. Assay Drug Dev Technol (2010) 0.75
Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. Public Health Genomics (2016) 0.75
Rb+ efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373). Assay Drug Dev Technol (2006) 0.75
The evangelizing patient. Virtual Mentor (2005) 0.75
Correlation of ride sharing service availability and decreased alcohol-related motor vehicle collision incidence and fatality. J Trauma Acute Care Surg (2020) 0.75
No marks for living in the real world of nursing. Nurs Stand (2003) 0.75